Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPC-3 CAR-T in Advanced Hepatocellular Carcinoma
NCT05620706Recruiting
- Sponsor
- Shenzhen University General Hospital
- Start
- Nov 2022
- Primary completion
- Oct 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of AZD7003 in hepatocellular carcinoma (HCC), sponsored by Shenzhen University General Hospital. Primary endpoint: Adverse Events and Serious Adverse Events at 30 days. Started Nov 2022; status: recruiting.
02
Drugs
AZD7003
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05620706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620706.